Bcl-2 inhibitors directly targeting the regulatory machinery of apoptosis30, as well as epigenetic therapy36 (including HDAC inhibitors), represent two promising alternative strategies for the treatment of myeloproliferative neoplasms, which may overcome resistance toward conventional chemotherapeutic drugs. Here, HDAC9 is linked to myeloproliferative disorder.